Welcome to our dedicated page for Ideaya Biosciences SEC filings (Ticker: IDYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IDEAYA Biosciences, Inc. (NASDAQ: IDYA) SEC filings page aggregates the company’s regulatory disclosures, including current reports on Form 8-K and other Exchange Act filings. These documents provide structured information on material events, financial results, collaborations, and governance decisions that affect the precision oncology business.
IDEAYA uses Form 8-K to report key developments such as quarterly financial results, material licensing agreements, and changes in major collaborations. For example, 8-K filings describe the exclusive license agreement with Servier for rights to darovasertib outside the United States, GlaxoSmithKline’s election to terminate a collaboration covering the Werner Helicase (IDE275) and Pol Theta (IDE705) programs, and positive clinical data from trials of darovasertib, IDE849, and IDE397. Other 8-Ks document annual meeting voting results, executive appointments, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4).
Filings also identify IDEAYA’s listing on The Nasdaq Global Select Market under the symbol IDYA and confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934. Investors can review these filings to understand how IDEAYA structures its collaborations, recognizes collaboration revenue, and discloses pipeline milestones and regulatory interactions.
On Stock Titan, IDEAYA’s SEC filings are updated as they are posted to EDGAR and can be paired with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly scan material terms of agreements, track clinical and regulatory updates reported under Item 8.01, and monitor financial disclosures reported under Item 2.02, without having to parse every line of the original filing.
IDEAYA Biosciences director Jeffrey Stein bought more company stock in the open market. On March 2, 2026, he purchased 50,000 shares of common stock in open-market transactions at a weighted average price of $32.9578 per share, with individual trades executed between $32.743 and $33.1999.
Following this purchase, he directly owns 54,281 common shares. An additional 3,363 shares are reported as held indirectly by his son.
IDEAYA Biosciences, Inc. attracted institutional interest from Point72-affiliated entities, which reported a 2.1% beneficial stake in the company’s common stock. As of the close of business on December 31, 2025, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen jointly reported beneficial ownership of 1,844,556 shares, with shared voting and dispositive power and no sole authority over any shares.
The shares are held in an investment fund managed by Point72 Asset Management, with Cubist Systematic Strategies, LLC and Point72 (DIFC) Limited acting as sub-advisers for portions of the position. The filers certify the holdings were not acquired to change or influence control of IDEAYA, consistent with a passive Schedule 13G filing and reflecting ownership of 5 percent or less of the class.
IDEAYA Biosciences outlines its precision oncology strategy and late‑stage pipeline in its annual report. The company focuses on synthetic lethality and antibody‑drug conjugates, with nine potential first‑in‑class product candidates across four cancer focus areas.
Darovasertib, an oral PKC inhibitor for uveal melanoma, leads the pipeline with multiple Phase 2/3 and Phase 3 trials planned or underway across metastatic, neoadjuvant and adjuvant settings, supported by FDA Breakthrough Therapy, Fast Track and Orphan Drug designations. In August 2025, IDEAYA licensed darovasertib ex‑US to Servier for a
The company is also advancing ADC/DDR combinations (including IDE849 and IDE161), MTAP‑pathway programs centered on MAT2A inhibitor IDE397, and next‑generation agents such as dual KAT6/7 inhibitor IDE574 and Werner helicase inhibitor IDE275. As of February 13, 2026, IDEAYA had 87,814,027 common shares outstanding, and its non‑affiliate equity market value was about
IDEAYA Biosciences reported fourth-quarter and full-year 2025 results alongside a major pipeline update. Collaboration revenue reached $10.9 million for the quarter and $218.7 million for 2025, driven by its darovasertib license with Servier. Cash, cash equivalents and marketable securities were about $1.05 billion as of December 31, 2025, and are expected to fund operations into 2030.
R&D expenses were $86.6 million in the quarter and $314.7 million for the year, while net loss narrowed to $83.3 million for the quarter and $113.7 million for the year, both improving versus 2024. The company highlighted progress for darovasertib in uveal melanoma, with required progression-free-survival events reached in its Phase 2/3 trial and topline data expected around the last week of March, and plans for three Phase 3 registrational trials by the first half of 2026.
IDEAYA also advanced additional programs, including IDE849 and IDE034 in antibody-drug conjugates, IDE161, IDE397 and IDE892 in MTAP-pathway targeting, and IDE574 in next-generation therapies, while preparing for commercial readiness and assuming full control of certain programs as GSK exits a prior collaboration.
IDEAYA Biosciences, Inc. received an updated ownership report from Capital Research Global Investors, which reports beneficial ownership of 5,279,675 shares of IDEAYA common stock. This represents 6.0% of the 87,666,408 shares believed to be outstanding as of the reported date.
Capital Research Global Investors has sole power to vote and dispose of all 5,279,675 shares and no shared voting or dispositive power. The filing states that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of IDEAYA.
IDEAYA Biosciences Chief Financial Officer receives new stock option grant. On January 30, 2026, CFO Joshua Bleharski was granted a stock option to purchase 170,000 shares of IDEAYA common stock at an exercise price of $32.19 per share, expiring on January 30, 2036.
According to the vesting terms, 25% of the option vests on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences granted its Chief Scientific Officer, Michael Anthony White, a stock option covering 190,000 shares of common stock on January 30, 2026. The option has an exercise price of $32.19 per share and is held directly by him.
According to the vesting terms, 25% of the option vests on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments over the following three years. This schedule makes the option fully vested and exercisable on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences’ Chief Medical Officer, Darrin Beaupre, reported a new stock option grant. On January 30, 2026, he received a stock option to buy 175,000 shares of IDEAYA common stock at an exercise price of $32.19 per share, expiring on January 30, 2036.
The option vests over four years starting from January 1, 2026: 25% of the shares vest on the first anniversary, then 1/48th of the total shares vest monthly so that the grant is fully vested and exercisable on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences, Inc. granted a new equity award to its Chief Commercial Officer, Stuart Dorman. On January 30, 2026, he received a stock option for 155,000 shares of common stock with an exercise price of $32.19 per share.
According to the vesting schedule, 25% of the option vests on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested and exercisable on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences President and CEO Yujiro Hata received a grant of stock options reported as of January 30, 2026. The award covers 600,000 options to buy IDEAYA common stock at an exercise price of $32.19 per share.
According to the vesting terms, 25% of the options vest on the first anniversary of January 1, 2026, and the remaining portion vests in equal monthly installments over the following three years, so the grant becomes fully vested on the fourth anniversary of that date.